Laura Parisio - Publications

Vedolizumab for the prevention and treatment of postoperative recurrence in Crohn's disease: A real- world latium net study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: March 18, 2026

Treat-to-Target in Ulcerative Colitis: How Soon Is Now?

Journal: Journal of clinical medicine

Published: December 03, 2025

Clinical Predictive Factors for the Development of Short Bowel Syndrome in a Cohort of Patients with Crohn's Disease: A Prospective Study.

Journal: Journal of clinical medicine

Published: August 11, 2025

Prognostic Significance of Different Endoscopic Scores in Post-Operative Crohn's Disease and their Role in Patients with Low-Risk Features.

Journal: Advances in therapy

Published: July 23, 2025

Thromboembolic and cardiovascular risk profiles in patients with ulcerative colitis initiating advanced therapies.

Journal: Therapeutic advances in gastroenterology

Published: July 16, 2025

Interleukin 23: Pathogenetic Involvement and Therapeutic Target for Ulcerative Colitis.

Journal: Journal of clinical medicine

Published: May 24, 2025

Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis.

Journal: Journal of clinical medicine

Published: December 31, 2023

Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients.

Journal: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology

Published: July 30, 2023

Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission.

Journal: Journal of gastrointestinal and liver diseases : JGLD

Published: June 20, 2023

Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: April 30, 2023

Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study.

Journal: Biomedicines

Published: March 03, 2022

Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.

Journal: European journal of gastroenterology & hepatology

Published: January 20, 2022